TAZASUBRATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C18H17NO3S2
Molecular Weight	359.462
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC2=C(C=C1)N=C(SC(C)(C(O)=O)C3=CC=CC=C3)S2

InChI

InChIKey=FREWOKWARGJVCE-UHFFFAOYSA-N

InChI=1S/C18H17NO3S2/c1-3-22-13-9-10-14-15(11-13)23-17(19-14)24-18(2,16(20)21)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3,(H,20,21)

HIDE SMILES / InChI

Molecular Formula	C18H17NO3S2
Molecular Weight	359.462
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3008771 | https://www.ncbi.nlm.nih.gov/pubmed/3014569

Tazasubrate was developed as a lipid-lowering agent. Tazasubrate was found to be a reliable and highly effective hypocholesterolemic agent. However, information about the current use of this compound is not available.

Approval Year

PubMed

Title	Date	PubMed
Mechanism of the plasma cholesterol lowering effect of tazasubrate in rats: accelerated plasma cholesterol transport with increased liver lipoprotein receptor activity.	1986-03	3014569
Pharmacological profile of tazasubrate, a new cholesterol-lowering agent.	1986-02	3008771
Influence of DL-2-phenyl[6-ethoxybenzothiazolyl-(2)-thio]propionic acid (EMD 34853) on gallstone formation in hamsters.	1984-02	6504964

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:49:02 GMT 2025` Edited by `admin` on `Mon Mar 31 18:49:02 GMT 2025`
Record UNII	6SGF1AP698
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAZASUBRATE

Official Name

English

tazasubrate [INN]

Preferred Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29703